Italia markets closed

Cosmo Pharmaceuticals N.V. (0RGI.L)

LSE - LSE Prezzo differito. Valuta in CHF.
Aggiungi a watchlist
65,90+0,81 (+1,24%)
Alla chiusura: 05:51PM GMT

Cosmo Pharmaceuticals N.V.

Riverside II
Sir John Rogerson’s Quay
Dublin 2
Ireland
353 1 817 0370
https://www.cosmopharma.com

Settore/i
Settore
Impiegati a tempo pieno319

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Mauro Severino AjaniFounder & Executive Chairman381,09kN/D1955
Mr. Alessandro E. Della Cha LL.MCEO & Executive Director1MN/D1963
Mr. Ngo Dinh NhanPresident of Cosmo Intelligent Medical DevicesN/DN/D1979
Mr. Giulio EvangelistiSVP of Manufacturing, Service and Security (IMD)N/DN/D1970
Mr. Niall DonnellyChief Financial OfficerN/DN/D1972
Mr. Marco LecchiChief Operating OfficerN/DN/D1964
Mr. Davide MalavasiQualified Person & Technical DirectorN/DN/D1973
Mr. Luigi LongoChief Scientific OfficerN/DN/D1979
Ms. Hazel WinchesterHead of Investor RelationsN/DN/D1971
Mr. Biagio ViganoChief People OfficerN/DN/D1974
Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in CHF.

Descrizione

Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology, endoscopy, dermatology, and healthtech worldwide. The company offers Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Lumeblue (methylene blue MMX), a diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy; Uceris/Cortiment, an oral tablet formulation which delivers budesonide directly to the lumen of the colon; Aemcolo/Relafalk, a GI antibiotic with MMX® technology and is approved for the treatment of travellers' diarrhoea; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Eleview, a medical device, which enables the safer and faster removal of colonic lesions; and GI Genius, a system that uses artificial intelligence to detect colorectal polyps during colonoscopy. It is also in the development of Breezula (clascoterone), a novel androgen receptor inhibitor that targets androgen receptors in the scalp, currently expecting phase III trials; Rifamycin SV MMX – IBS-D, a formulation to treat colonic infections and irritable bowel syndrome with diarrhoea, currently completed phase II proof of concept clinical trials; CB-03-10 (cortexolone 17 -valerate-21-propionate), an oral androgen receptor antagonist for treatment solid tumors, currently under phase I studies; and CB-01-33 (colesevelam) for the treatment of bile acid diarrhea, currently under preclinical studies. The company has development, distribution, and licensing agreements with Bausch Health, Ferring, China Medical System Holdings Limited, Medtronic, Parmascience Inc., RedHill Biopharma Ltd., Dr. Falk Pharma, Sun Pharmaceutical Industries Ltd., 3SBio, InfectoPharm, and Hyphens Pharma International Limited. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.

Governance aziendale

L'ISS Governance QualityScore di Cosmo Pharmaceuticals N.V. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.